Mucosal immunotherapy for protection from pneumonic infection with Francisella tularensis

Vaccine

Volumn 27, Issue 33, 2009, Pages 4424-4433

  Troyer, Ryan M ^a   Propst, Katie L ^a   Fairman, Jeff ^b   Bosio, Catherine M ^c   Dow, Steven W ^a  

^a Department of Environmental and Radiological Health Sciences   (United States)

^b Juvaris BioTherapeutics   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Bacterial; Cytokines; Lung; Mucosa; Rodent

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; DNA; GAMMA INTERFERON; INTERLEUKIN 12; LIPOSOME; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; BAGG ALBINO MOUSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG DELIVERY SYSTEM; FRANCISELLA TULARENSIS; GENE EXPRESSION; GROWTH INHIBITION; IMMUNOTHERAPY; INNATE IMMUNITY; LIVER; LUNG; LUNG ALVEOLUS MACROPHAGE; MACROPHAGE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RESPIRATORY TRACT MUCOSA; SPLEEN; SURVIVAL TIME; TULAREMIA;

ADMINISTRATION, INTRANASAL; ANIMALS; CELL LINE; CYTOKINES; DNA; FRANCISELLA TULARENSIS; IMMUNITY, MUCOSAL; IMMUNOTHERAPY; INTERFERON-GAMMA; KILLER CELLS, NATURAL; LIPOSOMES; LUNG; MACROPHAGES, ALVEOLAR; MICE; MICE, INBRED BALB C; MICE, INBRED ICR; MICE, KNOCKOUT; RESPIRATORY TRACT INFECTIONS; TULAREMIA;

EID: 67649378402     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.05.041     Document Type: Article

References (61)

1. Oyston P.C., Sjostedt A., and Titball R.W. Tularaemia: bioterrorism defence renews interest in Francisella tularensis. Nat Rev 2 December (12) (2004) 967-978
2. Conlan J.W., Chen W., Shen H., Webb A., and KuoLee R. Experimental tularemia in mice challenged by aerosol or intradermally with virulent strains of Francisella tularensis: bacteriologic and histopathologic studies. Microb Pathog 34 May (5) (2003) 239-248
3. Metzger D.W., Bakshi C.S., and Kirimanjeswara G. Mucosal immunopathogenesis of Francisella tularensis. Ann N Y Acad Sci 1105 June (2007) 266-283
4. Conlan J.W. Vaccines against Francisella tularensis-past, present and future. Exp Rev Vaccines 3 June (3) (2004) 307-314
5. Elkins K.L., Cowley S.C., and Bosio C.M. Innate and adaptive immunity to Francisella. Ann N Y Acad Sci 1105 June (2007) 284-324
6. Tarnvik A., Eriksson M., Sandstrom G., and Sjostedt A. Francisella tularensis-a model for studies of the immune response to intracellular bacteria in man. Immunology 76 July (3) (1992) 349-354
7. Elkins K.L., Rhinehart-Jones T.R., Stibitz S., Conover J.S., and Klinman D.M. Bacterial DNA containing CpG motifs stimulates lymphocyte-dependent protection of mice against lethal infection with intracellular bacteria. J Immunol 162 February (4) (1999) 2291-2298
8. Elkins K.L., Colombini S.M., Krieg A.M., and De Pascalis R. NK cells activated in vivo by bacterial DNA control the intracellular growth of Francisella tularensis LVS. Microb Infect/Institut Pasteur 11 January (1) (2009) 49-56
9. Duckett N.S., Olmos S., Durrant D.M., and Metzger D.W. Intranasal interleukin-12 treatment for protection against respiratory infection with the Francisella tularensis live vaccine strain. Infect Immun 73 April (4) (2005) 2306-2311
10. Pammit M.A., Budhavarapu V.N., Raulie E.K., Klose K.E., Teale J.M., and Arulanandam B.P. Intranasal interleukin-12 treatment promotes antimicrobial clearance and survival in pulmonary Francisella tularensis subsp. novicida infection. Antimicrob Agents Chemother 48 December (12) (2004) 4513-4519
11. Lembo A., Pelletier M., Iyer R., Timko M., Dudda J.C., West T.E., et al. Administration of a synthetic TLR4 agonist protects mice from pneumonic tularemia. J Immunol 180 June (11) (2008) 7574-7581
12. Zaks K., Jordan M., Guth A., Sellins K., Kedl R., Izzo A., et al. Efficient immunization and cross-priming by vaccine adjuvants containing TLR3 or TLR9 agonists complexed to cationic liposomes. J Immunol 176 June (12) (2006) 7335-7345
13. Dow S.W., Fradkin L.G., Liggitt D.H., Willson A.P., Heath T.D., and Potter T.A. Lipid-DNA complexes induce potent activation of innate immune responses and antitumor activity when administered intravenously. J Immunol 163 August (3) (1999) 1552-1561
14. Gursel I., Gursel M., Ishii K.J., and Klinman D.M. Sterically stabilized cationic liposomes improve the uptake and immunostimulatory activity of CpG oligonucleotides. J Immunol 167 September (6) (2001) 3324-3328
15. Whitmore M., Li S., and Huang L. LPD lipopolyplex initiates a potent cytokine response and inhibits tumor growth. Gene Therapy 6 November (11) (1999) 1867-1875
16. Goodyear A., Kellihan L., Bielefeldt-Ohmann H., Troyer R., Propst K., and Dow S. Protection from pneumonic infection with burkholderia species by inhalational immunotherapy. Infect Immun 77 April (4) (2009) 1579-1588
17. Bosio C.M., Bielefeldt-Ohmann H., and Belisle J.T. Active suppression of the pulmonary immune response by Francisella tularensis Schu4. J Immunol 178 April (7) (2007) 4538-4547
18. Bosio C.M., and Dow S.W. Francisella tularensis induces aberrant activation of pulmonary dendritic cells. J Immunol 175 November (10) (2005) 6792-6801
19. Karaghiosoff M., Steinborn R., Kovarik P., Kriegshauser G., Baccarini M., Donabauer B., et al. Central role for type I interferons and Tyk2 in lipopolysaccharide-induced endotoxin shock. Nat Immunol 4 May (5) (2003) 471-477
20. Fortier A.H., Slayter M.V., Ziemba R., Meltzer M.S., and Nacy C.A. Live vaccine strain of Francisella tularensis: infection and immunity in mice. Infect Immun 59 September (9) (1991) 2922-2928
21. Kirimanjeswara G.S., Golden J.M., Bakshi C.S., and Metzger D.W. Prophylactic and therapeutic use of antibodies for protection against respiratory infection with Francisella tularensis. J Immunol 179 July (1) (2007) 532-539
22. Sebastian S., Dillon S.T., Lynch J.G., Blalock L.T., Balon E., Lee K.T., et al. A defined O-antigen polysaccharide mutant of Francisella tularensis live vaccine strain has attenuated virulence while retaining its protective capacity. Infect Immun 75 May (5) (2007) 2591-2602
23. Chen W., KuoLee R., Shen H., and Conlan J.W. Susceptibility of immunodeficient mice to aerosol and systemic infection with virulent strains of Francisella tularensis. Microb Pathog 36 June (6) (2004) 311-318
24. Auerbuch V., Brockstedt D.G., Meyer-Morse N., O'Riordan M., and Portnoy D.A. Mice lacking the type I interferon receptor are resistant to Listeria monocytogenes. J Exp Med 200 August (4) (2004) 527-533
25. Carrero J.A., Calderon B., and Unanue E.R. Type I interferon sensitizes lymphocytes to apoptosis and reduces resistance to Listeria infection. J Exp Med 200 August (4) (2004) 535-540
26. Decker T., Muller M., and Stockinger S. The yin and yang of type I interferon activity in bacterial infection. Nat Rev Immunol 5 September (9) (2005) 675-687
27. Manca C., Tsenova L., Bergtold A., Freeman S., Tovey M., Musser J.M., et al. Virulence of a Mycobacterium tuberculosis clinical isolate in mice is determined by failure to induce Th1 type immunity and is associated with induction of IFN-alpha/beta. Proc Natl Acad Sci U S A 98 May (10) (2001) 5752-5757
28. Mancuso G., Midiri A., Biondo C., Beninati C., Zummo S., Galbo R., et al. Type I IFN signaling is crucial for host resistance against different species of pathogenic bacteria. J Immunol 178 Mar (5) (2007) 3126-3133
29. O'Connell R.M., Saha S.K., Vaidya S.A., Bruhn K.W., Miranda G.A., Zarnegar B., et al. Type I interferon production enhances susceptibility to Listeria monocytogenes infection. J Exp Med 200 August (4) (2004) 437-445
30. Schiavoni G., Mauri C., Carlei D., Belardelli F., Pastoris M.C., and Proietti E. Type I IFN protects permissive macrophages from Legionella pneumophila infection through an IFN-gamma-independent pathway. J Immunol 173 July (2) (2004) 1266-1275
31. Weigent D.A., Huff T.L., Peterson J.W., Stanton G.J., and Baron S. Role of interferon in streptococcal infection in the mouse. Microb Pathog 1 August (4) (1986) 399-407
32. Sellins K., Fradkin L., Liggitt D., and Dow S. Type I interferons potently suppress gene expression following gene delivery using liposome(-)DNA complexes. Mol Ther 12 September (3) (2005) 451-459
33. Gowen B.B., Fairman J., Smee D.F., Wong M.H., Jung K.H., Pace A.M., et al. Protective immunity against acute phleboviral infection elicited through immunostimulatory cationic liposome-DNA complexes. Antiviral Res 69 March (3) (2006) 165-172
34. Elkins K.L., Rhinehart-Jones T., Nacy C.A., Winegar R.K., and Fortier A.H. T-cell-independent resistance to infection and generation of immunity to Francisella tularensis. Infect Immun 61 March (3) (1993) 823-829
35. Elkins K.L., Rhinehart-Jones T.R., Culkin S.J., Yee D., and Winegar R.K. Minimal requirements for murine resistance to infection with Francisella tularensis LVS. Infect Immun 64 August (8) (1996) 3288-3293
36. Leiby D.A., Fortier A.H., Crawford R.M., Schreiber R.D., and Nacy C.A. In vivo modulation of the murine immune response to Francisella tularensis LVS by administration of anticytokine antibodies. Infect Immun 60 January (1) (1992) 84-89
37. Byrne P., McGuirk P., Todryk S., and Mills K.H. Depletion of NK cells results in disseminating lethal infection with Bordetella pertussis associated with a reduction of antigen-specific Th1 and enhancement of Th2, but not Tr1 cells. Eur J Immunol 34 September (9) (2004) 2579-2588
38. Habu S., Fukui H., Shimamura K., Kasai M., Nagai Y., Okumura K., et al. In vivo effects of anti-asialo GM1.I. Reduction of NK activity and enhancement of transplanted tumor growth in nude mice. J Immunol 127 July (1) (1981) 34-38
39. Kasai M., Iwamori M., Nagai Y., Okumura K., and Tada T. A glycolipid on the surface of mouse natural killer cells. Eur J Immunol 10 March (3) (1980) 175-180
40. Cole L.E., Santiago A., Barry E., Kang T.J., Shirey K.A., Roberts Z.J., et al. Macrophage proinflammatory response to Francisella tularensis live vaccine strain requires coordination of multiple signaling pathways. J Immunol 180 May (10) (2008) 6885-6891
41. Henry T., Brotcke A., Weiss D.S., Thompson L.J., and Monack D.M. Type I interferon signaling is required for activation of the inflammasome during Francisella infection. J Exp Med 204 May (5) (2007) 987-994
42. Mariathasan S., Weiss D.S., Dixit V.M., and Monack D.M. Innate immunity against Francisella tularensis is dependent on the ASC/caspase-1 axis. J Exp Med 202 October (8) (2005) 1043-1049
43. Ben Nasr A., Haithcoat J., Masterson J.E., Gunn J.S., Eaves-Pyles T., and Klimpel G.R. Critical role for serum opsonins and complement receptors CR3 (CD11b/CD18) and CR4 (CD11c/CD18) in phagocytosis of Francisella tularensis by human dendritic cells (DC): uptake of Francisella leads to activation of immature DC and intracellular survival of the bacteria. J Leukocyte Biol 80 October (4) (2006) 774-786
44. Fortier A.H., Leiby D.A., Narayanan R.B., Asafoadjei E., Crawford R.M., Nacy C.A., et al. Growth of Francisella tularensis LVS in macrophages: the acidic intracellular compartment provides essential iron required for growth. Infect Immun 63 April (4) (1995) 1478-1483
45. Polsinelli T., Meltzer M.S., and Fortier A.H. Nitric oxide-independent killing of Francisella tularensis by IFN-gamma-stimulated murine alveolar macrophages. J Immunol 153 August (3) (1994) 1238-1245
46. Anthony L.S., Morrissey P.J., and Nano F.E. Growth inhibition of Francisella tularensis live vaccine strain by IFN-gamma-activated macrophages is mediated by reactive nitrogen intermediates derived from L-arginine metabolism. J Immunol 148 March (6) (1992) 1829-1834
47. Cowley S.C., and Elkins K.L. Multiple T cell subsets control Francisella tularensis LVS intracellular growth without stimulation through macrophage interferon gamma receptors. J Exp Med 198 August (3) (2003) 379-389
48. Fortier A.H., Polsinelli T., Green S.J., and Nacy C.A. Activation of macrophages for destruction of Francisella tularensis: identification of cytokines, effector cells, and effector molecules. Infect Immun 60 March (3) (1992) 817-825
49. Green S.J., Nacy C.A., Schreiber R.D., Granger D.L., Crawford R.M., Meltzer M.S., et al. Neutralization of gamma interferon and tumor necrosis factor alpha blocks in vivo synthesis of nitrogen oxides from L-arginine and protection against Francisella tularensis infection in Mycobacterium bovis BCG-treated mice. Infect Immun 61 February (2) (1993) 689-698
50. Lindgren H., Stenman L., Tarnvik A., and Sjostedt A. The contribution of reactive nitrogen and oxygen species to the killing of Francisella tularensis LVS by murine macrophages. Microb Infect/Institut Pasteur 7 March (3) (2005) 467-475
51. Eigelsbach H.T., and Downs C.M. Prophylactic effectiveness of live and killed tularemia vaccines. I. Production of vaccine and evaluation in the white mouse and guinea pig. J Immunol 87 October (1961) 415-425
52. Klimpel G.R., Eaves-Pyles T., Moen S.T., Taormina J., Peterson J.W., Chopra A.K., et al. Levofloxacin rescues mice from lethal intra-nasal infections with virulent Francisella tularensis and induces immunity and production of protective antibody. Vaccine 26 December (52) (2008) 6874-6882
53. Wayne Conlan J., Shen H., Kuolee R., Zhao X., and Chen W. Aerosol-, but not intradermal-immunization with the live vaccine strain of Francisella tularensis protects mice against subsequent aerosol challenge with a highly virulent type A strain of the pathogen by an alphabeta T cell- and interferon gamma-dependent mechanism. Vaccine 23 March (19) (2005) 2477-2485
54. Wu T.H., Hutt J.A., Garrison K.A., Berliba L.S., Zhou Y., and Lyons C.R. Intranasal vaccination induces protective immunity against intranasal infection with virulent Francisella tularensis biovar A. Infect Immun 73 May (5) (2005) 2644-2654
55. Jia Q., Lee B.Y., Clemens D.L., Bowen R.A., and Horwitz M.A. Recombinant attenuated Listeria monocytogenes vaccine expressing Francisella tularensis IglC induces protection in mice against aerosolized Type A F. tularensis. Vaccine 27 February (8) (2009) 1216-1229
56. Bakshi C.S., Malik M., Mahawar M., Kirimanjeswara G.S., Hazlett K.R., Palmer L.E., et al. An improved vaccine for prevention of respiratory tularemia caused by Francisella tularensis SchuS4 strain. Vaccine 26 September (41) (2008) 5276-5288
57. Hall J.D., Craven R.R., Fuller J.R., Pickles R.J., and Kawula T.H. Francisella tularensis replicates within alveolar type II epithelial cells in vitro and in vivo following inhalation. Infect Immun 75 February (2) (2007) 1034-1039
58. Andersson H., Hartmanova B., Kuolee R., Ryden P., Conlan W., Chen W., et al. Transcriptional profiling of host responses in mouse lungs following aerosol infection with type A Francisella tularensis. J Med Microbiol 55 Mar (Pt 3) (2006) 263-271
59. Chase J.C., Celli J., and Bosio C.M. Direct and indirect impairment of human dendritic cell function by virulent Francisella tularensis Schu S4. Infect Immun 77 January (1) (2009) 180-195
60. Collazo C.M., Sher A., Meierovics A.I., and Elkins K.L. Myeloid differentiation factor-88 (MyD88) is essential for control of primary in vivo Francisella tularensis LVS infection, but not for control of intra-macrophage bacterial replication. Microb Infect/Institut Pasteur 8 March (3) (2006) 779-790
61. Lindgren H., Shen H., Zingmark C., Golovliov I., Conlan W., and Sjostedt A. Resistance of Francisella tularensis strains against reactive nitrogen and oxygen species with special reference to the role of KatG. Infect Immun 75 March (3) (2007) 1303-1309